Author

Julia Müller

Karlsruhe Institute of TechnologyPrimary ORCID profile (0009-0001-7519-7827 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Julia MülleriD1 paper · Technische Universität Braunschweig

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrew C.B. CatoiD· 1 shared Barbara BellettiiD· 1 shared Christine BlattneriD· 1 shared Christoph W. GrathwoliD· 1 shared Gary R. DavidsoniD· 1 shared Ilenia SegattoiD· 1 shared Janine WesslowskiiD· 1 shared Jutta StoberiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew C.B. CatoORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Distinct 2-phenyl-imidazo pyridine derivatives drive ER degradation and selectively impair proliferation of ER+ breast cancer cells via the aryl hydrocarbon receptor

Katrin Koellisch, Christine Blattner, Stefano Motta, Janine Wesslowski, Melanie Rothley, Simone Büchel, Savannah Sirounian, Julia Müller, Marina Grimaldi, Jutta Stober, Zoe Wammetsberger, Mengwu Pan, René Houtman, Christoph W. Grathwol, Ilenia Segatto, , Andrew C.B. Cato

The paper identifies X15695 as an AHR ligand that promotes ER degradation and inhibits ER+ breast cancer cell proliferation more effectively than fulvestrant.

bioRxiv · Jul 28, 2025 · PreprintCancer Biology